ERBB2 and non-small cell lung carcinoma: To date, the exploration of new targeted therapies remains an urgent need for advanced HER2‐mutant NSCLC due to a lack of effective anti‐HER2 inhibitors, with only traditional chemotherapies and T‐DXd being approved.